Adil Doganay Duru

919 total citations
26 papers, 648 citations indexed

About

Adil Doganay Duru is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Adil Doganay Duru has authored 26 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 13 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Adil Doganay Duru's work include Immune Cell Function and Interaction (15 papers), CAR-T cell therapy research (10 papers) and T-cell and B-cell Immunology (8 papers). Adil Doganay Duru is often cited by papers focused on Immune Cell Function and Interaction (15 papers), CAR-T cell therapy research (10 papers) and T-cell and B-cell Immunology (8 papers). Adil Doganay Duru collaborates with scholars based in Sweden, United States and Türkiye. Adil Doganay Duru's co-authors include Evren Alici, Michael Chrobok, Carin Dahlberg, Dhifaf Sarhan, Didem Özkazanç, Anna‐Maria Georgoudaki, Tolga Sütlü, Monica Raimo, Jan Spanholtz and Adnane Achour and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Immunology.

In The Last Decade

Adil Doganay Duru

25 papers receiving 638 citations

Peers

Adil Doganay Duru
Tom Just Denmark
Gina Scurti United States
Xiaoxia Tan United States
Anusara Daenthanasanmak United States
Justine Pascual Switzerland
Abhishek Asthana United States
Amy L. Rymaszewski United States
Ann‐Charlotte Björklund Sweden
A Modica Italy
Tom Just Denmark
Adil Doganay Duru
Citations per year, relative to Adil Doganay Duru Adil Doganay Duru (= 1×) peers Tom Just

Countries citing papers authored by Adil Doganay Duru

Since Specialization
Citations

This map shows the geographic impact of Adil Doganay Duru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adil Doganay Duru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adil Doganay Duru more than expected).

Fields of papers citing papers by Adil Doganay Duru

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adil Doganay Duru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adil Doganay Duru. The network helps show where Adil Doganay Duru may publish in the future.

Co-authorship network of co-authors of Adil Doganay Duru

This figure shows the co-authorship network connecting the top 25 collaborators of Adil Doganay Duru. A scholar is included among the top collaborators of Adil Doganay Duru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adil Doganay Duru. Adil Doganay Duru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kok, Nina, Didem Özkazanç, Simar Pal Singh, et al.. (2025). CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. iScience. 28(6). 112548–112548.
2.
Duru, Adil Doganay, Anna‐Maria Georgoudaki, Tanja D. de Gruijl, et al.. (2024). Bulk and single-cell transcriptomics identify gene signatures of stem cell-derived NK cell donors with superior cytolytic activity. PubMed. 32(4). 200870–200870. 3 indexed citations
3.
Raimo, Monica, Susan Gibbs, Tanja D. de Gruijl, et al.. (2023). Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. iScience. 26(7). 107078–107078. 4 indexed citations
4.
Georgoudaki, Anna‐Maria, Haiping Liu, Didem Özkazanç, et al.. (2022). Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. Journal of Hematology & Oncology. 15(1). 164–164. 107 indexed citations
5.
Saha, Tanmoy, Chunxiao Cui, Arpita Kulkarni, et al.. (2021). Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90. Frontiers in Molecular Biosciences. 8. 754443–754443. 9 indexed citations
6.
Duru, Adil Doganay, Renhua Sun, Nadir Kadri, et al.. (2020). Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination. PLoS Pathogens. 16(5). e1008244–e1008244. 13 indexed citations
7.
Rossi, Fiorella, et al.. (2020). Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells. PLoS ONE. 15(9). e0239238–e0239238. 9 indexed citations
8.
Chrobok, Michael, Didem Özkazanç, Benjamin J. Josey, et al.. (2020). Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. Frontiers in Immunology. 11. 40–40. 47 indexed citations
9.
Özkazanç, Didem, Anna‐Maria Georgoudaki, Benjamin J. Josey, et al.. (2019). Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer. European Journal of Immunology. 49(8). 1278–1290. 37 indexed citations
10.
Doorduijn, Elien M., Renhua Sun, Marjolein Sluijter, et al.. (2018). The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability. The Journal of Immunology. 200(8). 2860–2868. 8 indexed citations
11.
Lund, Johan, Astrid Gruber, Birgitta Lauri, et al.. (2018). Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma. Cancer Medicine. 7(6). 2256–2268. 3 indexed citations
12.
13.
Doorduijn, Elien M., Adil Doganay Duru, Cláudia C. Oliveira, et al.. (2016). The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer. The Journal of Immunology. 196(5). 2327–2334. 12 indexed citations
14.
Sork, Helena, Joel Z. Nordin, Janne J. Turunen, et al.. (2016). Lipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency. Molecular Therapy — Nucleic Acids. 5. e290–e290. 16 indexed citations
15.
Duru, Adil Doganay, Tolga Sütlü, Katarina Uttervall, et al.. (2015). Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLoS ONE. 10(9). e0138248–e0138248. 6 indexed citations
16.
Uttervall, Katarina, Adil Doganay Duru, Johan Lund, et al.. (2014). The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE. 9(7). e101819–e101819. 42 indexed citations
17.
Madhurantakam, Chaithanya, Adil Doganay Duru, Tatyana Sandalova, John R. Webb, & Adnane Achour. (2012). Inflammation-Associated Nitrotyrosination Affects TCR Recognition through Reduced Stability and Alteration of the Molecular Surface of the MHC Complex. PLoS ONE. 7(3). e32805–e32805. 18 indexed citations
18.
Kavak, Erşen, Ayaz Najafov, Nuri Öztürk, et al.. (2010). Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets. Cellular Signalling. 22(10). 1523–1535. 18 indexed citations
19.
Brodin, Petter, Tadepally Lakshmikanth, Ramit Mehr, et al.. (2010). Natural Killer Cell Tolerance Persists Despite Significant Reduction of Self MHC Class I on Normal Target Cells in Mice. PLoS ONE. 5(10). e13174–e13174. 25 indexed citations
20.
Bilecen, Kıvanç, Adil Doganay Duru, Tolga Sütlü, et al.. (2005). Triticum durum Metallothionein. Journal of Biological Chemistry. 280(14). 13701–13711. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tom Just Breakdown of academic impact, for papers by Gina Scurti Breakdown of academic impact, for papers by Xiaoxia Tan Breakdown of academic impact, for papers by Anusara Daenthanasanmak Breakdown of academic impact, for papers by Justine Pascual Breakdown of academic impact, for papers by Abhishek Asthana Breakdown of academic impact, for papers by Amy L. Rymaszewski Breakdown of academic impact, for papers by Ann‐Charlotte Björklund Breakdown of academic impact, for papers by A Modica
Rankless by CCL
2026